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Abstract 
Introduction Up to half of all smokers develop clinically significant chronic obstructive pulmonary disease 
(COPD). Gaps exist in the implementation and uptake of evidencebased guidelines for managing COPD in 
primary care. We describe the methodology of a cluster randomised controlled trial (cRCT) evaluating the 
efficacy and costeffectiveness of an interdisciplinary model of care aimed at reducing the burden of 
smoking and COPD in Australian primary care settings. Methods and analysis A cRCT is being undertaken 
to evaluate an interdisciplinary model of care (RADICALS - Review of Airway Dysfunction and 
Interdisciplinary Community-based care of Adult Long-term Smokers). General practice clinics across 
Melbourne, Australia, are identified and randomised to the intervention group (RADICALS) or usual care. 
Patients who are current or ex-smokers, of at least 10 pack years, including those with an existing 
diagnosis of COPD, are being recruited to identify 280 participants with a spirometry-confirmed diagnosis 
of COPD. Handheld lung function devices are being used to facilitate case-finding. RADICALS includes 
individualised smoking cessation support, home-based pulmonary rehabilitation and home medicines 
review. Patients at control group sites receive usual care and Quitline referral, as appropriate. Follow-ups 
occur at 6 and 12months from baseline to assess changes in quality of life, abstinence rates, health 
resource utilisation, symptom severity and lung function. The primary outcome is change in St George's 
Respiratory Questionnaire score of patients with COPD at 6months from baseline. Ethics and 
dissemination This project has been approved by the Monash University Human Research Ethics 
Committee and La Trobe University Human Ethics Committee (CF14/1018 - 2014000433). Results of the 
study will be disseminated in peer-reviewed journals and research conferences. If the intervention is 
successful, the RADICALS programme could potentially be integrated into general practices across 
Australia and sustained over time. 
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ABSTRACT
Introduction Up to half of all smokers develop clinically 
significant chronic obstructive pulmonary disease (COPD). 
Gaps exist in the implementation and uptake of evidence-
based guidelines for managing COPD in primary care. 
We describe the methodology of a cluster randomised 
controlled trial (cRCT) evaluating the efficacy and cost-
effectiveness of an interdisciplinary model of care aimed 
at reducing the burden of smoking and COPD in Australian 
primary care settings.
Methods and analysis A cRCT is being undertaken to 
evaluate an interdisciplinary model of care (RADICALS 
— Review of Airway Dysfunction and Interdisciplinary 
Community-based care of Adult Long-term Smokers). 
General practice clinics across Melbourne, Australia, 
are identified and randomised to the intervention group 
(RADICALS) or usual care. Patients who are current or 
ex-smokers, of at least 10 pack years, including those 
with an existing diagnosis of COPD, are being recruited 
to identify 280 participants with a spirometry-confirmed 
diagnosis of COPD. Handheld lung function devices are 
being used to facilitate case-finding. RADICALS includes 
individualised smoking cessation support, home-based 
pulmonary rehabilitation and home medicines review. 
Patients at control group sites receive usual care and 
Quitline referral, as appropriate. Follow-ups occur at 6 and 
12 months from baseline to assess changes in quality of 
life, abstinence rates, health resource utilisation, symptom 
severity and lung function. The primary outcome is change 
in St George’s Respiratory Questionnaire score of patients 
with COPD at 6 months from baseline.
Ethics and dissemination This project has been 
approved by the Monash University Human Research 
Ethics Committee and La Trobe University Human Ethics 
Committee (CF14/1018 – 2014000433). Results of the 
study will be disseminated in peer-reviewed journals and 
research conferences. If the intervention is successful, the 
RADICALS programme could potentially be integrated into 
general practices across Australia and sustained over time.
Trial registration number ACTRN12614001155684; Pre-
results.
InTRoduCTIon
Chronic obstructive pulmonary 
disease (COPD)  (COPD) is a major public 
health problem. Symptoms and compli-
cations of the condition can greatly affect 
patients’ ability to undertake daily activities, 
impair quality of life and result in exten-
sive use of health services. According to the 
World Health Organisation (WHO), COPD 
is the fourth leading cause of death and is 
projected to be the third leading cause of 
death by 2030 (potentially contributing to 
8.6% of deaths worldwide).1 In Australia, 
the overall prevalence of moderate to severe 
COPD in adults aged 40 years and over is 
7.5% (95% CI 5.7% to 9.4%).2 3 The preva-
lence increases to 29.2% (95% CI 18.1% to 
40.2%) among those aged 75 years and over.3 
In 2012, 4% of all deaths among Australians 
Strengths and limitations of this study
 ► A large implementation trial in primary care involving 
current smokers, ex-smokers and patients with an 
existing diagnosis of chronic obstructive pulmonary 
disease.
 ► Cluster randomisation of general practices to 
minimise the risk of contamination, and blinded 
outcome assessment.
 ► Open-labelled trial; participants and health 
professionals are not blinded, with a potential for 
Hawthorne effect.
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aged 55 years and over was attributed to COPD.4 The rate 
of hospitalisation for COPD among those aged 55 and 
over was 1052 per 100 000 population.5 It was estimated 
that the rate of COPD management in Australian general 
practices during 2013–2014 was 1.0 (95% CI 0.9 to 1.1) 
per 100 encounters, an increase from 0.8 (95% CI 0.7 to 
0.9) in 2004–2005.6
The Global Initiative for Chronic Obstructive Lung 
Disease (GOLD) defines COPD as ‘a common preventable 
and treatable disease, [which] is characterised by persistent 
airflow limitation that is usually progressive and associated with 
an enhanced chronic inflammatory response in the airways and 
the lung to noxious particles or gases’.7 The greatest and most 
preventable risk factor for the development of COPD 
is tobacco smoking, with up to 50% smokers eventually 
developing clinically significant COPD.8
Numerous guidelines for the diagnosis, management 
and prevention of COPD have been published. The 
Lung Foundation Australia (LFA) and the Thoracic 
Society of Australia and New Zealand have summarised 
current evidence and developed a set of guidelines for 
the optimal management of people with COPD, known as 
the COPD-X Plan.9 The COPD-X guidelines recommend 
key components of COPD management, including lung 
function testing to confirm diagnosis, optimising both 
pharmacological and non-pharmacological therapies 
including pulmonary rehabilitation, smoking cessation 
support, vaccinations, appropriate oxygen therapy, devel-
opment of support networks and self-management plans, 
and appropriate management of exacerbations.9 More 
recently, a concise guide of the COPD-X Plan has been 
published and distributed for use in primary care.10
Despite numerous guidelines for COPD management, 
studies conducted in other countries have revealed gaps 
in health practitioner knowledge of and adherence to 
these guidelines.11 Audits of primary care professionals’ 
adherence to COPD guidelines in Australia and overseas 
have consistently shown deviations from optimal pharma-
cological treatment, lack of referrals to pulmonary reha-
bilitation and underutilisation of spirometry in COPD 
diagnosis.12–21
Underdiagnosis and misdiagnosis of COPD in the 
Australian population are common.2 22–24 This may be 
due to the general underutilisation of spirometry in both 
hospital and primary care settings.22 24–27 It is estimated 
that at least 600 000 Australians have moderate to severe 
COPD of which they are unaware and therefore not 
receiving appropriate treatment.22 28 29 There is a need for 
greater awareness of COPD among primary care health 
providers to promote earlier diagnosis and more timely 
initiation of appropriate treatments.22
Optimal pharmacological treatment is important in 
controlling the symptoms of COPD and preventing 
exacerbations. Deviations from recommended pharma-
cological treatments have been identified, especially in 
relation to use of corticosteroids (inhaled and oral) and 
antibiotics.21 30 In recent years, multiple new therapeutic 
agents for managing COPD have been introduced onto 
the Australian market. These agents include new long-
acting muscarinic antagonists (LAMAs), inhaled cortico-
steroid/long-acting beta agonist (LABA) combinations 
and LAMA/LABA combinations. New inhaler devices 
have also been developed for the delivery of these novel 
agents, creating additional challenges for health profes-
sionals and patients alike.
Pulmonary rehabilitation is a key non-pharmacological 
component in the management of COPD. Improvements 
in the quality of life of patients with COPD following 
pulmonary rehabilitation can be seen in the Chronic 
Respiratory Disease Questionnaire scores in areas of 
dyspnoea, fatigue, mastery and emotional function, along 
with an enhancement in patients’ sense of control over 
their condition.31 Despite the compelling evidence of its 
benefits, access to pulmonary rehabilitation programmes 
remains limited in Australia. It is estimated that only 
5%–10% of patients with moderate to severe COPD use 
pulmonary rehabilitation services in Australia.32 Simi-
larly low rates of pulmonary rehabilitation uptake are 
reported across the developed world.33 34 A combination 
of programme-related factors and barriers at both the 
patient and referrer level contributes to low access rates. 
Poor knowledge of the benefits of pulmonary rehabilita-
tion in the management of COPD, limited knowledge of 
the referral process,32 35 inconvenience of travel to hospi-
tal-based programmes, concerns from culturally and 
linguistically diverse patients, and the lack of perceived 
benefit of pulmonary rehabilitation have been reported 
to affect the uptake and completion of these programmes 
by eligible patients.36–38
Interdisciplinary practice-based interventions have 
shown to lead to positive changes in healthcare, including 
improvements in patient care.39 An interdisciplinary 
approach could potentially benefit the management of 
patients with COPD. Many different healthcare profes-
sionals are involved in the crucial components of COPD 
management, including smoking cessation support, 
pharmacotherapy, self-management education and exer-
cise training. Effects of an interdisciplinary approach 
on COPD patient outcomes have been analysed. Studies 
have demonstrated the potential benefits of an interdis-
ciplinary approach on patient quality of life, symptom 
control, exercise tolerance and hospital episodes.40 41 
Other studies have shown improvements in the level of 
follow-up, self-reported daily activities, pulmonary reha-
bilitation attendance and disease knowledge among 
patients with COPD.24 42
Primary care services in Australia are predomi-
nantly delivered by the nation’s 22 000 general practi-
tioners (GPs), nearly all of whom working in privately 
owned general practice settings. Primary healthcare 
providers also include nurses (general practice nurses, 
community nurses and nurse practitioners), allied health 
professionals, midwives, pharmacists, dentists and Aborig-
inal health workers. The primary healthcare services 
include health promotion, prevention and screening, 
early intervention, treatment and management.43 Clinical 
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care provided within general practice is predominantly 
reimbursed by fee-for-service payments (through the 
Australian Federal Government’s Medical Benefits 
Scheme (MBS)), although GPs are also able to attract 
copayments for their services. The MBS in Australia allows 
GPs to claim for services surrounding chronic disease 
management. These include GP preparation of chronic 
disease management plans, plans for ongoing treatment 
by a multidisciplinary team (GP along with at least two 
other health professionals) and for pharmacist-con-
ducted home medication review (HMR) services.44
Currently, delivery of pulmonary rehabilitation 
programmes and HMRs is on a GP referral basis. Remu-
neration is available to pharmacists for HMR services 
(home visit and generation of a report of findings and 
recommendations to the referring practitioner) through 
the MBS. However, there is no remuneration pathway for 
private physiotherapists providing pulmonary rehabilita-
tion programmes in the community. A formal model of 
care bringing together services provided by various health 
professionals for the management of patients with COPD 
is lacking. An interdisciplinary model of care involving 
GPs and other practice staff, pharmacists and physiother-
apists has not been evaluated in the Australian primary 
care setting.
Aims and objectives
The primary aim of this study is to determine the efficacy, 
for patients with COPD, of an interdisciplinary model of 
care (RADICALS — Review of Airway Dysfunction and 
Interdisciplinary Community-based care of Adult Long-
term Smokers) compared with usual care on health-re-
lated quality of life (HRQoL), measured at 6 months 
using the St George’s Respiratory Questionnaire (SGRQ).
The secondary objectives are to determine the propor-
tion of smokers with spirometry-confirmed COPD and 
evaluate the efficacy of RADICALS compared with usual 
care on smoking abstinence, nicotine dependence, lung 
function, symptom severity, health resource utilisation 
(unplanned GP visits, hospitalisations and emergency 
department presentations), anxiety and depression 
scores, and medication adherence at 6 and 12 months. 
If the interdisciplinary model is shown to be effective, an 
economic evaluation will be conducted to compare the 
costs and benefits of the model with usual care.
METhodS
This is a cluster randomised controlled trial in primary 
care clinics across Melbourne, Australia. Eligible primary 
care clinics that consent are randomised to either inter-
vention (interdisciplinary care group=ICG) or control 
(usual care group=UCG). Participants are recruited from 
each clinic and receive the intervention or usual care 
depending on the allocation of the clinic. Each partici-
pant is screened for eligibility at baseline and completes 
follow-up interviews at 6 and 12 months from baseline. 
The RADICALS intervention is delivered to participants 
from ICG clinics (see figure 1).
Practice recruitment
Eligible practices are identified through advertisements 
and consultation with the Eastern Melbourne PHN and 
key informants. Direct approaches to clinics (telephone 
contact, direct emails with study information, brief 
presentations at GP continuing professional development 
events, door knocking and so on) may also be employed. 
The practice is formally enrolled into the study upon 
receipt of a signed practice agreement form.
Inclusion and exclusion criteria
Group or solo primary care practices with at least 1000 
patients in their databases are eligible for inclusion in the 
trial. Primary care practices must also be willing to accom-
modate research staff at the practice or have personnel at 
the practice willing to undertake training and dedicate 
time to specific tasks of the research project.
Randomisation: allocation, concealment and sequence generation
Primary care clinics are block-randomised, using block 
sizes of four and six, into ICG or UCG using a web-based 
randomisation program managed by an independent 
agency. Research assistants (RAs) and practice staff on 
site are notified of the allocation of their clinic. Cluster 
randomisation of clinics minimises the risk of contamina-
tion across intervention and control groups when partici-
pants from the same clinic are managed by the same GPs 
and/or clinic staff. However, observed outcomes among 
participants sampled within the same clinic may still be 
more similar than outcomes observed in participants 
sampled from different clinics. The sample size has been 
increased depending on the size of clinics randomised 
and the degree of similarity of outcomes among members 
of the same clinic, measured in terms of the intracluster 
or intraclass correlation coefficient.45
Participant recruitment
Eligible patient participants are identified through 
searching of the practice clinical database by an RA 
employed at each site or trained practice staff. Practice 
staff are also informed of the study and asked to refer 
patients who meet eligibility criteria. Letters with an 
Expression of Interest form are sent from the practice 
to eligible patients formally inviting them to take part 
in the study. Those interested in the study are asked to 
return the completed form in a reply-paid envelope. 
Non-respondents are sent up to two reminders. Informed 
consent is sought after provision of study information, 
a plain language statement and opportunities for any 
questions. A toll-free number is set up and is available to 
potential participants for this purpose. Baseline data are 
collected after written informed consent is obtained.
Inclusion and exclusion criteria
Current or ex-smokers with a history of at least 10 pack 
years of smoking, aged 40 years or older, including those 
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with an existing diagnosis of COPD, who had two or 
more visits to the practice in the previous 12 months, are 
included. Two or more visits will indicate patient engage-
ment with the practice. Those with no history of smoking 
are eligible only if they have spirometry-confirmed COPD.
Exclusion criteria include patients with a terminal 
illness (anticipated survival <12 months), those unable 
to provide informed consent (eg, cognitive impairment), 
those with pre-existing interstitial lung disease, unstable 
cardiovascular status, comorbidities preventing partic-
ipation in an exercise training programme or contrain-
dications to spirometry (including abdominal/thoracic/
neurosurgery/ocular surgery in the preceding 6 weeks, 
pneumothorax in the preceding 6 weeks, haemop-
tysis of unknown origin, open pulmonary tuberculosis, 
thoracic/abdominal/cerebral aneurysms, angiogram in 
the previous 24 hours, recent pulmonary embolus and 
others listed in the American Thoracic Society/European 
Respiratory Society (ATS/ERS) guidelines46). Those 
patients who have completed a pulmonary rehabilitation 
programme in the previous 24 months are also excluded 
from the study.
Allocation of participants
All participants recruited from a clinic receive the inter-
vention or usual care depending on the allocation of the 
clinic (ie, whether the clinic is allocated to ICG or UCG).
Early identification of COPD: case-finding and spirometry
Case-finding occurs in patients using the handheld COPD-6 
device (Vitalograph, Ennis, Ireland). If COPD is suspected 
during the initial testing (ie, forced expiratory volume in 
1 second (FEV1)/forced expiratory volume in 6 seconds 
(FEV6)<0.75
22 47) or if the participant has difficulty using 
the handheld device, spirometry is performed. Spirom-
etry testing is performed by trained RAs using Easy on-PC 
spirometers (ndd Medizintechnik AG, Zürich, Switzer-
land), following the ATS/ERS guidelines.46 Pre-broncho-
dilator and post-bronchodilator spirometry are performed 
by participants at baseline. Readings are interpreted using 
an algorithm. Participants with post-bronchodilator FEV1/ 
forced vital capacity (FVC) readings<0.7 are defined as 
having COPD. Results are communicated to the partic-
ipant’s clinic, where diagnosis is confirmed after taking 
patient symptoms and risk factors into consideration. 
Those with an existing diagnosis of COPD undergo testing 
to confirm their diagnosis, where appropriate. If the partic-
ipant already had spirometry in the previous 3 months, that 
report is used for confirmation of diagnosis. Assistance 
from respiratory scientists and/or respiratory physicians is 
available for the interpretation of challenging reports.
Interdisciplinary care group
GPs and other clinic staff from the ICG who are involved 
in the project are offered specific training. Training 
Figure 1 RADICALS study flow diagram. COPD, chronic obstructive pulmonary disease; GP, general practitioner.
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focuses on the COPD-X Plan for the management of 
COPD, spirometry training and the ‘Supporting smoking 
cessation: a guide for health professionals’.48
Participants in ICG clinics receive the RADICALS model 
of care. The key components of RADICALS include inten-
sive, individualised smoking cessation support from the 
RA, home-based pulmonary rehabilitation from a specifi-
cally trained physiotherapist and a home medicines review 
from a consultant pharmacist (accredited to undertake 
medication reviews). The intervention is coordinated by 
the RA at each site under the supervision of each partici-
pant’s GP and clinic staff. Participants are free to decline 
or discontinue any or all of the intervention components 
at any point in time; reasons for declining or discontin-
uing are obtained where possible. In addition, patients 
with a diagnosis of COPD receive the LFA booklet ‘Better 
Living with Chronic Obstructive Pulmonary Disease – A Patient 
Guide’49 and management by their GP according to the 
COPD-X Plan.
Smoking cessation support
Individualised smoking cessation support is coordinated 
by the RA at each site and offered to participants who are 
current smokers, regardless of COPD diagnosis. In ICG 
clinics, the consultant pharmacist performing HMRs is 
also involved in providing smoking cessation support for 
smokers who have COPD. The intervention(s) offered will 
be individually tailored to the patient’s smoking status, 
needs and preferences. QUIT resources and a treatment 
algorithm50 are used to guide treatment. Pharmaco-
therapy (over-the-counter and/or prescription) is recom-
mended, if appropriate. If prescription medications are 
required to assist smoking cessation, these are discussed 
with the participant’s GP. Smoking cessation support is 
offered at an initial consultation, with follow-up phone 
calls at 1 week and 1 month from the initial consulta-
tion, as appropriate. Telephone follow-ups re-emphasise 
the importance of quitting and long-term abstinence, 
and also discuss issues surrounding relapse and relapse 
prevention strategies.
Home-based pulmonary rehabilitation
A home-based pulmonary rehabilitation model is 
employed,51 delivered by a specifically trained phys-
iotherapist. The model includes one home visit with 
weekly follow-up telephone calls using a motivational 
interviewing approach to build confidence and set goals. 
Home-based exercise training is prescribed based on each 
patient’s exercise capacity. A goal for walking distance is 
set and distance is recorded using a pedometer. Partic-
ipants are encouraged to exercise for 30 min, five times 
per week, and to record the completion of this activity in 
a home diary. Resistance training for the arms and legs 
uses daily activities and equipment that is readily available 
in the home environment (eg, step-ups on an internal or 
external step, sit to stand from a standard height chair, 
water bottles for upper limb weights). Participants are 
contacted by a physiotherapist each week by telephone for 
7 weeks. During the weekly telephone calls, disease-spe-
cific self-management training and exercise progression 
are achieved using the principles of motivational inter-
viewing. Exercise goals and health goals are discussed and 
documented each week in the home diary. The physio-
therapist also refers to the LFA ‘Better Living with Chronic 
Obstructive Pulmonary Disease – A Patient Guide’49 booklet 
during discussions.
Home medicines review
A home medicines review52 from a consultant pharmacist 
identifies any medication-related problems and devia-
tions from COPD-X treatment guidelines. The consultant 
pharmacist interviews participants at their homes and 
assesses their medication use, including inhaler tech-
nique. Interventions for optimising medication adher-
ence and inhaler use are also offered, if required. The 
pharmacist generates a report for the GP, including 
recommendations for optimising medication use and 
adherence to COPD-X.
usual care group
GPs in UCG practices continue to provide routine care 
to their patients. GPs in these practices receive a copy of 
the COPD-X Plan and the ‘Supporting Smoking Cessation: a 
guide for health professionals’48 publication. Patient partic-
ipants in UCG practices receive routine care from their 
GP and Quitline referral, if appropriate. Those identified 
to have COPD receive a copy of the LFA ‘Better Living with 
Chronic Obstructive Pulmonary Disease – A Patient Guide’49 
booklet.
data collection and follow-up
Baseline data from each practice are collected at the 
time of clinic enrolment. General information on prac-
tice staffing and specialist services provided (including 
respiratory services provision) is obtained from the prac-
tice manager and/or practice staff using a standard data 
collection form. Data collection from participants occurs 
at baseline (time of recruitment) and at two follow-up 
time points: 6 and 12 months from baseline. Baseline 
data collection occurs through a face-to-face interview 
with participants at the clinic of recruitment. Telephone, 
mail or face-to-face follow-up is conducted to retain as 
many participants in the trial as possible and reduce the 
amount of missing data. Information on reason(s) for 
withdrawal from the study are obtained where possible.
Patient demographics such as age, gender, nationality, 
language, education, employment, marital status, income, 
living arrangements, concession card status (ie, eligibility 
for reduced out-of-pocket cost of healthcare services and 
less expensive medicines) and healthcare visits in the 
past 6 months are collected at baseline. Patients’ medical 
records are reviewed to obtain medical and medica-
tion history. Smoking-related information is collected, 
including smoking status, age at which smoking started, 
smoking-related behaviours of participants and those 
of friends and housemates, money spent on cigarettes, 
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and information on previous smoking cessation attempts 
and outcomes. Preferred methods of smoking cessation, 
motivation and confidence to give up smoking are also 
determined.
The Charlson Comorbidity Index is used to collect 
information on comorbidities.53 Exhaled carbon 
monoxide (CO) levels are measured using a handheld 
piCO Smokerlyzer (Bedfont Scientific, Maidstone, Kent, 
UK) to confirm self-report of abstinence. COPD-6 (Vita-
lograph, Ennis, Ireland) readings are obtained as part of 
case-finding. Pre-bronchodilator and post-bronchodilator 
spirometry are performed at baseline, and post-broncho-
dilator spirometry is performed in patients with COPD at 
6-month and 12-month follow-ups.
The following data are collected from participants, 
where appropriate, using validated tools at baseline, 6 
and 12 months:
 ► Heaviness of Smoking Index (HSI)54: This is a 
two-item scale measuring nicotine dependence based 
on the number of cigarettes smoked per day and time 
to first cigarette of the day. A score of 1–2 indicates 
very low nicotine dependence and a score >5 indicates 
high nicotine dependence.
 ► Smoking Self-Efficacy Scale55: This is a nine-item scale 
that assesses confidence in the ability to abstain from 
smoking in certain high-risk situations. A 5-point 
scale ranging from ‘Not at all tempted’ to ‘Extremely 
tempted’ is used to answer questions about tempta-
tion to smoke in various situations. A higher score 
suggests greater temptation to smoke.
 ► Readiness to Quit Ladder (adapted)56 57: This scale 
has 10 response options that assess motivation to quit 
smoking along a continuum. Responses range from 
‘Not considering quitting in the near future’ to ‘Have 
already quit smoking’. A higher score suggests greater 
motivation to quit smoking.
 ► Hospital Anxiety and Depression Scale (HADS)58: 
This is a 14-item questionnaire developed to screen 
for the presence of anxiety and depression.
 ► Visual Analogue Scales (VAS) for motivation and 
confidence: 10-point scales are used to assess partici-
pants’ motivation and confidence to give up smoking.
Data collected from participants identified to have 
COPD using validated tools at baseline, 6 and 12 months 
include:
 ► SGRQ59: This is a 50-item questionnaire developed 
to measure health status (quality of life) in patients 
with diseases of airways obstruction. Questions are 
answered on three domains: symptoms (frequency 
and severity), activities that cause or are limited by 
breathlessness, and impact (on social functioning, 
psychological disturbances). Scores range from 0 to 
100, with higher scores indicating worse HRQoL.
 ► COPD Assessment Test (CAT)60: This is an eight-
item questionnaire used to measure the health 
status of patients with COPD. Each item is formatted 
as a semantic 6-point differential scale (0–5) with 
contrasting adjectives. All items can be scored as a 
single scale ranging from 0 to 40. Higher scores indi-
cate worse health.
 ► Modified Medical Research Council (mMRC) Dysp-
noea Scale61 62: This is a scale consisting of five state-
ments describing levels of dyspnoea based on the 
extent to which various physical activities precipi-
tate breathlessness. Each statement corresponds to 
a grade; grade 0 indicates no dyspnoea and grade 
4 indicates severe dyspnoea to the point of almost 
incapacity.
 ► EQ-5D63: This is a generic instrument used as a 
measure of health outcome. This instrument obtains 
information across the five dimensions of mobility, 
self-care, usual activities, pain/discomfort and 
anxiety/depression. Each dimension is scored on a 
5-point Likert scale (no problems/slight problems/
moderate problems/severe problems/extreme prob-
lems). The EQ-VAS, a visual analogue scale contained 
within the EQ-5D questionnaire for recording an indi-
vidual’s rating of their current HRQoL state, is also 
administered.
 ► Beliefs and Behaviour Questionnaire (BBQ)64: This 
30-item questionnaire measures beliefs, experiences 
and adherent behaviour on 5-point Likert scales. 
Medication adherence will be assessed using the 
TABS (Tool for Adherence Behaviour and Screening) 
questionnaire, a subscale within the BBQ.
Participants who receive the HMR are asked to complete 
an anonymous satisfaction questionnaire, adapted from 
surveys used in previous studies.65–68 GP feedback on 
each HMR conducted is also sought by asking them to 
complete a questionnaire when they receive the report 
from the consultant pharmacist.
Data from participants will be stored in locked filing 
cabinets at the practices or at Monash University. 
Collected data will be de-identified, entered into an 
electronic database and saved on a password-protected 
computer. Data will be stored under these conditions 
for the duration of the trial and for the required time 
period after trial end, as stipulated by the Monash 
University regulations. Only investigators and research 
staff involved in the trial will have access to participant 
data. An independent data and safety monitoring board 
(DSMB) has been set up comprising a respiratory consul-
tant with experience in development of clinical guide-
lines for management of COPD and clinical research; a 
physiotherapist with expertise in translation of research 
evidence into clinical practice, especially pulmonary 
rehabilitation; and a GP with experience in conducting 
clinical studies in primary care and reviewing the 
evidence base for treatment in respiratory diseases. The 
DSMB will meet periodically and as required to evaluate 
study progress, including patient accrual and retention, 
and review cumulative study data to evaluate safety, study 
conduct, and scientific validity and integrity of the trial. 
The DSMB will also provide independent advice to the 
investigators whether the study should continue without 
change, be modified or terminated.
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Blinding
All outcome measure assessments are conducted by RAs 
blinded to treatment allocation. All possible measures are 
taken to prevent revealing treatment allocation to RAs 
conducting these assessments.
Primary endpoint
The primary endpoint is change in HRQoL, as measured 
by the SGRQ, at 6 months from baseline. The SGRQ 
is extensively used in interventional studies involving 
patients with all COPD severities. The use of the SGRQ 
enables capturing of HRQoL effects of the RADICALS 
intervention across the spectrum of COPD severity.
Secondary endpoints
Secondary outcomes of the trial are:
 ► exhaled CO-verified 7-day point prevalence absti-
nence in smokers at 6 and 12 months from baseline; 
a participant with an exhaled CO level <7 parts per 
million (ppm)will be considered abstinent
 ► change in lung function (FEV1) in patients with COPD 
at 6 and 12 months from baseline
 ► change in SGRQ score in patients with COPD at 12 
months from baseline
 ► change in CAT score in patients with COPD at 6 and 
12 months from baseline
 ► change in response to EQ-5D in patients with COPD 
at 6 and 12 months from baseline
 ► change in dyspnoea (mMRC score) in patients with 
COPD at 6 and 12 months from baseline
 ► change in HSI score of smokers at 6 and 12 months 
from baseline
 ► change in frequency of emergency department pres-
entations or hospitalisations in patients with COPD at 
6 and 12 months from baseline
 ► change in frequency of COPD-related unplanned GP 
visits in patients with COPD at 6 and 12 months from 
baseline
 ► change in anxiety and depression scores on the HADS 
in patients with COPD at 6 and 12 months from 
baseline
 ► change in medication adherence as measured by the 
TABS questionnaire in patients with COPD at 6 and 
12 months from baseline
 ► proportion of smokers with spirometry-confirmed 
COPD at baseline
 ► patient satisfaction with the home medicines review 
and GP feedback on home medicines review based on 
completion of standard surveys.
Sample size
Change in SGRQ score at 6 months from enrolment is the 
primary efficacy endpoint. A difference of at least four 
points between treatment arms is considered clinically 
significant.59 Assuming a conservative SD of 10 points,59 
99 participants per group (80% power and p=0.05) will 
be required. Adjusting for clustering by practice (intra-
class correlation=0.0169 and cluster size 10), the required 
sample is 108 per arm. To allow for 20% attrition after 
enrolment, recruitment will continue until 280 (140 in 
each arm) participants are enrolled in the trial. There-
fore, at least 28 primary care practices need to be recruited 
and 14 each randomised to ICG and UCG. From each 
practice, 50 smokers will be screened to identify 10 with 
COPD (post-bronchodilator FEV1/FVC<0.7).
70 A sample 
of 1400 smokers would allow the proportion of patients 
with COPD to be estimated within ±2% (approximately), 
with a 95% CI from 18% to 22%. Recruitment of 700 
smokers in each arm would allow a difference of 6% in 
abstinence rates to be detected (eg, 12% in control vs 
18% in intervention) with 86% power at the 5% level of 
significance.
Statistical analysis
Baseline demographic and clinical characteristics will 
be summarised using proportions, means and SD, or 
medians and IQRs, as appropriate. Changes in study vari-
ables within the intervention and control practices will be 
examined and any differences in outcomes between the 
two groups will be compared. Unadjusted and adjusted 
analyses will be performed with analysis by COPD status 
(existing or no existing COPD diagnosis) as a covariate 
and an interaction of the intervention with this covariate. 
The mean change in SGRQ scores at 6 months in each 
treatment group will be estimated. Differences between 
groups and 95% CIs will be determined. Multivariable 
analyses will be performed using multiple linear regres-
sion for continuous outcomes and multiple logistic regres-
sion for binary outcomes. All regression analyses will be 
adjusted for clustering, prognostic variables and potential 
confounders. Data will be analysed using the intention-to-
treat principle. Sensitivity analyses using multiple imputa-
tion methods may be performed to account for missing 
data. Sensitivity analysis using different exhaled CO 
cut-off values (3-10ppm) will be performed. Participants 
who are lost to follow-up will be regarded as smokers (ie, 
deemed to have relapsed smoking at that point). Per-pro-
tocol analysis will also be undertaken.
Economic evaluation
Economic evaluation of health interventions is important 
in aiding decision-making processes, especially in matters 
of government reimbursement.71 Various costing infor-
mation will be collected as part of the trial. Direct costs 
of the intervention will include staff time, consum-
ables, communications, overheads and staff transpor-
tation. Information on the cost of the intervention will 
be collected by staff within the trial. Medicare Benefits 
Scheme and Pharmaceutical Benefits Scheme data may 
also be used to assign costs to intervention components. 
Data on the use of health services including GP, specialist 
and emergency department visits, and hospitalisations 
will be collected from patients, and the associated costs 
with the use of these will be considered for evaluation.
The EQ-5D will be used to classify health states 
and determine an individual’s utility of health state. 
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Quality-adjusted life years (QALYs), which can capture 
the impact on both quantity and quality of life (ie, 
mortality and morbidity),72 will be generated using utility 
weights outlined in previous literature.71 An incremental 
cost-effectiveness ratio will be used to compare the differ-
ences in costs and differences in gains in QALYs between 
the intervention and usual care. Other outcomes consid-
ered for economic analysis may include change in SGRQ 
scores and change in number of individuals abstaining 
from smoking.
Trial status
The trial is in the recruitment phase at the time of manu-
script submission.
The first participant was enrolled on 5 March 2015. 
End of data collection is expected in April 2018.
dISCuSSIon
Diagnosis and management of COPD are suboptimal 
in Australian primary care despite the availability of 
evidence-based treatment guidelines. Effective inter-
ventions are required for case-finding and diagnosis of 
COPD, maintaining and improving HRQoL, promoting 
self-management and improving participation in exercise 
programmes. Studies involving multidisciplinary, inte-
grated care models have signposted various issues that 
should be addressed in future studies for better COPD 
management. These include better patient involvement, 
more individualised and intensive smoking cessation 
interventions, new ways of delivering pulmonary reha-
bilitation, and prompt intervention following COPD 
diagnosis.24 40 42 The RADICALS model of care aims to 
address these aspects. The model emphasises an interdis-
ciplinary approach to COPD management by providing 
patient-centred care through collaborative working rela-
tionships between GPs, nursing staff, other practice staff, 
pharmacists, physiotherapists and respiratory physicians/
scientists. Individualised smoking cessation support, 
HMRs, home-based pulmonary rehabilitation and inter-
disciplinary care are the key components of RADICALS.
HMRs can identify existing medication-related prob-
lems and make recommendations regarding COPD and 
smoking cessation therapy. Medication reviews have the 
potential to improve adherence to evidence-based phar-
macological treatments for COPD. A home-based pulmo-
nary rehabilitation programme is known to be as effective 
as centre-based pulmonary rehabilitation.51 Home-based 
pulmonary rehabilitation may overcome some of the 
barriers associated with centre-based rehabilitation, such 
as inconvenience of travel and long waiting periods.
The proposed RADICALS model has the potential to 
reduce the burden and morbidity associated with smoking 
and COPD, and improve HRQoL for affected patients. If 
the intervention is successful, the RADICALS programme 
could potentially be integrated into general practices across 
Australia and sustained over time. Resources and services 
already exist in the Australian community that would aid its 
implementation. It should be noted that the HMR service 
and the home-based pulmonary rehabilitation programme 
offered as part of RADICALS are funded solely through the 
trial, and not through the MBS. Outcomes of this study may 
inform integration of this service model into primary care, 
including service payments through the MBS. Our case-
finding methods are informed by a previous COPD case-
finding study conducted in Australian primary care,47 and 
the LFA recommendations for case-finding based on FEV1/
FEV6 readings,
22 potentially adding to the evidence base in 
this area.
Our study is a large implementation trial in primary care 
involving current smokers, ex-smokers and patients with 
an existing diagnosis of COPD. Some strengths include 
the cluster randomisation of general practices, which mini-
mises the risk of contamination, and outcome assessment 
by staff blinded to treatment allocation. Due to the nature 
of the intervention, blinding of participants and health 
professionals is not possible, introducing the potential for 
Hawthorne effect. The RADICALS intervention is primarily 
designed for Australian primary care based on the COPD-X 
guidelines, which do not use the GOLD ABCD grading 
system for symptoms, potentially limiting extrapolation of 
our findings to studies using the ABCD grading. Neverthe-
less, we use the mMRC Dyspnoea Scale and the CAT for 
symptom assessment in participants, allowing us to carry out 
subgroup analyses, if required. Moreover, the ABCD assess-
ment tool performed no better than the spirometric grades 
for mortality prediction or other important health outcomes 
in COPD.73–75 Using an FEV1/FEV6 cut-off of 0.75 may result 
in over-referral of participants for spirometry; however, local 
guideline recommendations have been followed.
Follow-up method for participants may differ 
depending on participant availability/preference, poten-
tially introducing detection and/or response bias. Sensi-
tivity analyses will be performed where possible to identify 
any effects of follow-up method on outcomes.
EThICS And dISSEMInATIon
Any proposed modifications to the protocol will be 
approved by the investigator team, before being commu-
nicated to relevant parties.
dissemination
Results of the trial will be submitted to peer-reviewed 
journals, and presented at both national and interna-
tional research conferences, where possible.
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